OTCPK:PTKF.Y

Stock Analysis Report

Executive Summary

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia.

Snowflake

Fundamentals

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Kalbe Farma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.02%

PTKF.Y

2.4%

US Pharmaceuticals

2.3%

US Market


1 Year Return

33.2%

PTKF.Y

-7.7%

US Pharmaceuticals

5.6%

US Market

Return vs Industry: PTKF.Y exceeded the US Pharmaceuticals industry which returned -7.7% over the past year.

Return vs Market: PTKF.Y exceeded the US Market which returned 5.6% over the past year.


Shareholder returns

PTKF.YIndustryMarket
7 Day0.02%2.4%2.3%
30 Day-1.9%1.1%-1.0%
90 Dayn/a-1.5%-0.7%
1 Year35.0%33.2%-5.4%-7.7%7.9%5.6%
3 Year-8.4%-11.7%18.8%10.5%45.6%36.3%
5 Year-14.0%-18.5%26.4%13.1%65.8%47.6%

Price Volatility Vs. Market

How volatile is Kalbe Farma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kalbe Farma undervalued compared to its fair value and its price relative to the market?

31.04x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: PTKF.Y ($23.18) is trading above our estimate of fair value ($18.59)

Significantly Undervalued: PTKF.Y is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PTKF.Y is poor value based on its PE Ratio (31x) compared to the Pharmaceuticals industry average (16.2x).

PE vs Market: PTKF.Y is poor value based on its PE Ratio (31x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: PTKF.Y is poor value based on its PEG Ratio (3.9x)


Price to Book Ratio

PB vs Industry: PTKF.Y is overvalued based on its PB Ratio (5.3x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Kalbe Farma forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

8.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTKF.Y's forecast earnings growth (8% per year) is above the savings rate (2.7%).

Earnings vs Market: PTKF.Y's earnings (8% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: PTKF.Y's earnings are forecast to grow, but not significantly.

Revenue vs Market: PTKF.Y's revenue (7.9% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: PTKF.Y's revenue (7.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: PTKF.Y's Return on Equity is forecast to be low in 3 years time (16.6%).


Next Steps

Past Performance

How has Kalbe Farma performed over the past 5 years?

4.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PTKF.Y's earnings have grown by 4.8% per year over the past 5 years.

Accelerating Growth: PTKF.Y's earnings growth over the past year (4%) is below its 5-year average (4.8% per year).

Earnings vs Industry: PTKF.Y earnings growth over the past year (4%) underperformed the Pharmaceuticals industry 24.3%.


Return on Equity

High ROE: PTKF.Y's Return on Equity (16.6%) is considered low.


Return on Assets

ROA vs Industry: PTKF.Y has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: PTKF.Y's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Kalbe Farma's financial position?


Financial Position Analysis

Short Term Liabilities: PTKF.Y's short term assets (IDR10,661.2B) exceeds its short term liabilities (IDR2,658.4B)

Long Term Liabilities: PTKF.Y's short term assets (10,661.2B) exceeds its long term liabilities (857.8B)


Debt to Equity History and Analysis

Debt Level: PTKF.Y's debt to equity ratio (4.9%) is considered satisfactory

Reducing Debt: PTKF.Y's debt to equity ratio has reduced from 6.8% to 4.9% over the past 5 years.

Debt Coverage: PTKF.Y's debt is well covered by operating cash flow (380.3%).

Interest Coverage: PTKF.Y earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: PTKF.Y has a high level of physical assets or inventory.

Debt Coverage by Assets: PTKF.Y's debt is covered by short term assets (assets are 14.317530x debt).


Next Steps

Dividend

What is Kalbe Farma's current dividend yield, its reliability and sustainability?

1.57%

Current Dividend Yield


Dividend Yield vs Market

company1.6%marketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Years1.7%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: PTKF.Y's dividend (1.57%) is higher than the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: PTKF.Y's dividend (1.57%) is low compared to the top 25% of dividend payers in the US market (3.76%).

Stable Dividend: PTKF.Y's dividend payments have been volatile in the past 10 years.

Growing Dividend: PTKF.Y's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (48.8%), PTKF.Y's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PTKF.Y's dividends in 3 years are forecast to be well covered by earnings (45.5% payout ratio).


Next Steps

Management

What is the CEO of Kalbe Farma's salary, the management and board of directors tenure and is there insider trading?

6.0yrs

Average management tenure


CEO

- Vidjongtius (55yo)

2.3yrs

Tenure

0

Mr. Vidjongtius has been President Director of PT Kalbe Farma Tbk. since June 5, 2017. He served as Corporate Secretary of PT. Kalbe Farma Tbk. since March 28, 2008 until June 14, 2017. Mr. Vidjongtius ser ...


Management Age and Tenure

6.0yrs

Average Tenure

55yo

Average Age

Experienced Management: PTKF.Y's management team is seasoned and experienced (6 years average tenure).


Board Age and Tenure

4.9yrs

Average Tenure

55yo

Average Age

Experienced Board: PTKF.Y's board of directors are considered experienced (4.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • - Vidjongtius (55yo)

    President Director

    • Tenure: 2.3yrs
  • Bernadus Winata (55yo)

    Independent Director & Corporate Secretary

    • Tenure: 2.3yrs
  • Kurniawan Suhartono (54yo)

    Head of Internal Audit Unit

    • Tenure: 6yrs
  • Lanny Soputro (55yo)

    Director of Corporate Human Resource

    • Tenure: 12.8yrs
  • Sie Djohan (52yo)

    Director of Corporate Business Development

    • Tenure: 2.3yrs
  • Lukito Gozali

    Head of Investor Relations

    • Tenure: 0yrs

Board Members

  • - Vidjongtius (55yo)

    President Director

    • Tenure: 2.3yrs
  • Santoso Oen (55yo)

    Commissioner

    • Tenure: 11.8yrs
  • Bernadette Ruth Setiady (57yo)

    President Commissioner

    • Tenure: 2.3yrs
  • Ferdinand Aryanto (47yo)

    Commissioner

    • Tenure: 11.8yrs
  • Bernadus Winata (55yo)

    Independent Director & Corporate Secretary

    • Tenure: 2.3yrs
  • Djonny Tjahyadi (55yo)

    Director

    • Tenure: 4.4yrs
  • Ongkie Tedjasurja (60yo)

    Director

    • Tenure: 8.8yrs
  • Lucky Slamet (66yo)

    Independent Commissioner

    • Tenure: 5.4yrs
  • Bujung Nugroho (55yo)

    Director

    • Tenure: 5.4yrs
  • Sie Djohan (52yo)

    Director of Corporate Business Development

    • Tenure: 2.3yrs

Company Information

PT Kalbe Farma Tbk.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Kalbe Farma Tbk.
  • Ticker: PTKF.Y
  • Exchange: OTCPK
  • Founded: 1966
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp77.578t
  • Listing Market Cap: Rp5.469b
  • Shares outstanding: 46.88b
  • Website: https://www.kalbe.co.id

Number of Employees


Location

  • PT Kalbe Farma Tbk.
  • Gedung KALBE
  • Jl. Let. Jend Suprapto Kav 4
  • Jakarta
  • Jakarta Raya
  • 10510
  • Indonesia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KLBFIDX (Indonesia Stock Exchange)YesCommon SharesIDIDRJan 1992
PTKF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1992
PTKF.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDMar 2010

Biography

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceutical, Consumer Health,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:10
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.